Patients with severe asthma initiated dupilumab and tezepelumab treatment more often than other biologics between 2022 and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback